Alvotech (NASDAQ:ALVO) Sees Large Volume Increase – Here’s Why

Alvotech (NASDAQ:ALVO) shares saw unusually-strong trading volume on Thursday . Approximately 740,220 shares changed hands during mid-day trading, an increase of 23% from the previous session’s volume of 602,097 shares.The stock last traded at $3.15 and had previously closed at $3.19.

Analysts Set New Price Targets

A number of analysts have weighed in on ALVO shares. Wall Street Zen cut Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. Weiss Ratings cut Alvotech from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.60.

Alvotech Trading Down 1.4%

The firm has a market capitalization of $949.19 million, a price-to-earnings ratio of -12.54 and a beta of 0.19. The firm has a fifty day moving average price of $3.56 and a 200 day moving average price of $3.93.

Alvotech (NASDAQ:ALVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.09) EPS for the quarter. Alvotech had a negative return on equity of 11.92% and a negative net margin of 14.36%.The business had revenue of $105.90 million for the quarter. As a group, equities analysts predict that Alvotech will post 0.05 EPS for the current fiscal year.

Institutional Trading of Alvotech

Several large investors have recently made changes to their positions in ALVO. Magnetar Financial LLC acquired a new stake in shares of Alvotech in the third quarter valued at $86,000. Orion Porfolio Solutions LLC acquired a new position in Alvotech during the 3rd quarter worth about $92,000. ProShare Advisors LLC lifted its position in Alvotech by 24.0% during the 4th quarter. ProShare Advisors LLC now owns 13,826 shares of the company’s stock worth $71,000 after buying an additional 2,675 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Alvotech by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,211 shares of the company’s stock worth $78,000 after acquiring an additional 3,110 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in Alvotech by 218.0% during the 2nd quarter. Bank of America Corp DE now owns 16,623 shares of the company’s stock worth $152,000 after acquiring an additional 11,395 shares during the last quarter.

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).